Budget Impact Analysis of Rosiglitazone for the Treatment of Type 2 Diabetes
碩士 === 國防醫學院 === 藥學研究所 === 95 === Background: A full pharmacoeconomic evaluation should include not only a cost-effectiveness analysis but also a budget impact analysis (BIA). The latter seems more important to a decision maker because BIA addresses the issue of financial affordability after a new d...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2007
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/18907507712388538861 |